| abstract |
The present disclosure relates to compounds (I') and their use in methods of treating disorders associated with fluid retention or salt overload, such as heart failure (especially congestive heart failure), chronic kidney disease, end-stage renal disease, Liver disease and fluid retention induced by peroxisome proliferator-activated receptor (PPAR) gamma agonists. The present disclosure also relates to compounds (I') and their use in methods of treating hypertension. The present disclosure also relates to Compounds (I') and their use in methods of treating gastrointestinal disorders, including treating or alleviating pain associated with gastrointestinal disorders. |